WallStreetZenWallStreetZen

NASDAQ: RPRX
Royalty Pharma PLC Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for RPRX

Based on 6 analysts offering 12 month price targets for Royalty Pharma PLC.
Min Forecast
$47.00+11.03%
Avg Forecast
$52.67+24.42%
Max Forecast
$57.00+34.66%

Should I buy or sell RPRX stock?

Based on 6 analysts offering ratings for Royalty Pharma PLC.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RPRX stock forecasts and price targets.

RPRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Morgan Stanley
Top 15%
86
Strong BuyMaintains$51.00+20.48%2022-12-06
JP Morgan
Bottom 23%
23
Strong BuyMaintains$52.00+22.84%2022-10-18
Tigress Financial
Bottom 5%
5
BuyMaintains$57.00+34.66%2022-07-14
UBS
Bottom 19%
19
Strong BuyInitiates Coverage On$47.00+11.03%2022-06-14
ScotiaBank
Bottom 50%
50
BuyInitiates Coverage On$53.00+25.21%2022-05-13
Goldman Sachs
Top 15%
86
Strong BuyInitiates Coverage On$56.00+32.29%2022-04-27

1 of 1

Forecast return on equity

Is RPRX forecast to generate an efficient return?
Company
26.93%
Industry
13.69%
Market
62.68%
RPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RPRX forecast to generate an efficient return on assets?
Company
15.87%
Industry
13.17%
RPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RPRX earnings per share forecast

What is RPRX's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$2.99+162.28%
Avg 2 year Forecast
$3.57+213.16%
Avg 3 year Forecast
$4.03+253.51%
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

RPRX revenue forecast

What is RPRX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$2.3B+3.14%
Avg 2 year Forecast
$2.6B+15.5%
Avg 3 year Forecast
$2.9B+27.02%
RPRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RPRX earnings growth forecast

How is RPRX forecast to perform vs Biotechnology companies and vs the US market?
Company
52.82%
Industry
7.77%
Market
17.05%
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

RPRX revenue growth forecast

How is RPRX forecast to perform vs Biotechnology companies and vs the US market?
Company
8.35%
Industry
24.03%
Market
6.67%
RPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RPRX$42.33$52.67+24.42%Strong Buy
SGEN$125.24$163.83+30.82%Buy
ALNY$238.01$226.31-4.91%Buy
ARGX$389.52$436.42+12.04%Strong Buy
GMAB$45.84$38.15-16.78%Hold
View Top Biotech Stocks

Royalty Pharma Stock Forecast FAQ

Is Royalty Pharma Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: RPRX) stock is to Strong Buy RPRX stock.

Out of 6 analysts, 4 (66.67%) are recommending RPRX as a Strong Buy, 2 (33.33%) are recommending RPRX as a Buy, 0 (0%) are recommending RPRX as a Hold, 0 (0%) are recommending RPRX as a Sell, and 0 (0%) are recommending RPRX as a Strong Sell.

If you're new to stock investing, here's how to buy Royalty Pharma stock.

What is RPRX's earnings growth forecast for 2022-2024?

(NASDAQ: RPRX) Royalty Pharma's forecast annual earnings growth rate of 52.82% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.77%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 17.05%.

Royalty Pharma's earnings in 2022 is $506,820,000.On average, 4 Wall Street analysts forecast RPRX's earnings for 2022 to be $1,815,593,167, with the lowest RPRX earnings forecast at $1,760,943,206, and the highest RPRX earnings forecast at $1,852,026,475. On average, 5 Wall Street analysts forecast RPRX's earnings for 2023 to be $2,167,781,808, with the lowest RPRX earnings forecast at $2,064,554,103, and the highest RPRX earnings forecast at $2,271,009,513.

In 2024, RPRX is forecast to generate $2,447,103,834 in earnings, with the lowest earnings forecast at $2,325,659,475 and the highest earnings forecast at $2,574,620,411.

What is RPRX's revenue growth forecast for 2022-2024?

(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 8.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 6.67%.

Royalty Pharma's revenue in 2022 is $2,247,167,000.On average, 3 Wall Street analysts forecast RPRX's revenue for 2022 to be $1,407,421,105,338, with the lowest RPRX revenue forecast at $1,398,099,643,563, and the highest RPRX revenue forecast at $1,415,251,837,607. On average, 3 Wall Street analysts forecast RPRX's revenue for 2023 to be $1,576,042,954,479, with the lowest RPRX revenue forecast at $1,553,501,059,783, and the highest RPRX revenue forecast at $1,619,047,616,444.

In 2024, RPRX is forecast to generate $1,733,235,067,772 in revenue, with the lowest revenue forecast at $1,723,136,969,322 and the highest revenue forecast at $1,743,333,773,445.

What is RPRX's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: RPRX) forecast ROA is 15.87%, which is higher than the forecast US Biotechnology industry average of 13.17%.

What is RPRX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year RPRX price target, the average RPRX price target is $52.67, with the highest RPRX stock price forecast at $57.00 and the lowest RPRX stock price forecast at $47.00.

On average, Wall Street analysts predict that Royalty Pharma's share price could reach $52.67 by Dec 6, 2023. The average Royalty Pharma stock price prediction forecasts a potential upside of 24.42% from the current RPRX share price of $42.33.

What is RPRX's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: RPRX) Royalty Pharma's current Earnings Per Share (EPS) is $1.14. On average, analysts forecast that RPRX's EPS will be $2.99 for 2022, with the lowest EPS forecast at $2.90, and the highest EPS forecast at $3.05. On average, analysts forecast that RPRX's EPS will be $3.57 for 2023, with the lowest EPS forecast at $3.40, and the highest EPS forecast at $3.74. In 2024, RPRX's EPS is forecast to hit $4.03 (min: $3.83, max: $4.24).

What is RPRX's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: RPRX) forecast ROE is 26.93%, which is considered strong.
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.